| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the years ended December 31, 2024 and 2023:
Schedule
of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2024 |
|
|
2023 |
|
| |
|
Year ended December 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Preclinical, clinical trial and other costs |
|
$ |
5,450,963 |
|
|
$ |
3,817,669 |
|
| Research and development personnel expense(1) |
|
|
1,818,183 |
|
|
|
1,981,849 |
|
| Research
and development expense |
|
|
|
|
|
|
|
|
| General and administrative personnel expense(2) |
|
|
1,981,756 |
|
|
|
1,737,792 |
|
| General and administrative expense |
|
|
|
|
|
|
|
| Administrative and facilities expense(3) |
|
|
2,800,304 |
|
|
|
3,919,751 |
|
| Interest income, net |
|
|
(201,088 |
) |
|
|
(335,541 |
) |
| Total |
|
$ |
11,850,118 |
|
|
$ |
11,121,520 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $169,414 and $363,956 for the year ended December
31, 2024, and 2023, respectively. |
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $186,925 and $387,854 for the year ended December
31, 2024, and 2023, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and
other administrative costs. |
|